SubHero Banner

Pepaxto® (melphalan flufenamide) – New orphan drug approval

February 26, 2021 - Oncopeptides announced the FDA approval of Pepaxto (melphalan flufenamide), in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

Download PDF